Heilmann L
Abt. für Perinatologie, Klinikum Essen.
Z Geburtshilfe Perinatol. 1989 Sep-Oct;193(5):219-25.
Plasma volume contraction in pregnancy is diagnosed by an increase of hematocrit above 38%. Hydroxyethylstarch was administered to 30 patients with hemoconcentration alone, to 36 patients with fetal growth weight retardation and to two patients with pre-eclampsia. In the present study the tolerance and effectiveness of middle molecular hydroxyethylstarch as volume replacement was studied. The data presented a significant decrease in the incidence of small for date babies (from 52% to 34%). In addition to these findings, hematocrit, erythrocyte aggregation and plasma viscosity were decreased and cardiac output was increased. By twenty three women we registered a newborn weight below the 10th percentile according to Hohenauer. The impaired rheological properties of blood in this group were associated with a decrease of cardiac output. We conclude that hydroxyethylstarch is a safe (no maternal-fetal transfer and only a small incidence of starch storage (1.4% of patients) in the placenta) and effective colloid substance for plasma volume expansion in pregnancy.
妊娠期血浆容量减少通过血细胞比容升高超过38%来诊断。对30例单纯血液浓缩患者、36例胎儿生长发育迟缓患者和2例先兆子痫患者给予羟乙基淀粉。在本研究中，研究了中分子羟乙基淀粉作为容量替代物的耐受性和有效性。数据显示小于胎龄儿的发生率显著降低（从52%降至34%）。除了这些发现外，血细胞比容、红细胞聚集和血浆粘度降低，心输出量增加。我们记录到23名女性所产新生儿体重低于霍赫瑙尔标准的第10百分位数。该组血液流变学特性受损与心输出量降低有关。我们得出结论，羟乙基淀粉是一种安全（无母婴转移，胎盘淀粉储存发生率仅为1.4%的患者）且有效的胶体物质，可用于妊娠期血浆容量扩充。
